
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Telix Pharmaceuticals Limited is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $3.3 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.755 - $4.69 |
---|---|
50-day moving average | $4.2003 |
200-day moving average | $2.8396 |
Target price | $2.2 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.089 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Revenue TTM | $3.3 million |
---|---|
Gross profit TTM | $942,000 |
Return on assets TTM | -34.65% |
Return on equity TTM | -73.87% |
Profit margin | 0% |
Book value | 0.212 |
Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $0.755 up to $4.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.4932. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a development collaboration agreement with ARTMS Products Inc. for the manufacture of its prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11 injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). Telix Pharmaceuticals Limited has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.
Steps to owning and managing Top Shelf International shares.
Steps to owning and managing K12 Inc shares from Australia.
Steps to owning and managing 2U Inc shares from Australia.
Steps to owning and managing Chegg Inc shares from Australia.
Steps to owning and managing Liberty Financial Group shares.
Steps to owning and managing Cettire shares.